Hormonal
Modern incretin-based and multi-agonist peptide therapies (GLP-1, GIP/GLP-1, and triple agonists) induce double-digit percentage weight loss (15-25%) that approaches or exceeds outcomes historically associated with bariatric surgery.
If you have obesity, modern peptide therapies like tirzepatide or semaglutide can help you lose 15-25% of your body weight, which is significantly more than older drugs and approaches the results of surgery. These treatments work by targeting the hormones that control your hunger and metabolism. While they are injectable and can be expensive, they are increasingly considered first-line treatments, especially if you have other health risks like heart disease or diabetes. You should discuss these options with your doctor to see if they are appropriate for you.
Agents such as tirzepatide and Retatrutide have exceeded previous pharmacological efficacy thresholds, achieving mean weight reductions of 20–25% in clinical trials. These outcomes approach those traditionally associated with bariatric surgery and raise important questions regarding the future positioning of pharmacological versus surgical interventions in obesity management.
Why this rating
Based on large phase-3 clinical trials (STEP, SURMOUNT) and narrative synthesis of high-quality evidence.
Source
Modern pharmacotherapy of obesity: molecular mechanisms, clinical efficacy and future therapeutic directions
Navneeth Selvan · International Journal of Basic & Clinical Pharmacology · 2026
DOI 10.18203/2319-2003.ijbcp20260443
More from this paper
- Semaglutide 2.4 mg significantly reduces major adverse cardiovascular events (MACE) in individuals with overweight or obesity without diabetes, establishing pharmacological weight loss as cardiovascular risk-modifying therapy.Strong
- Classical anti-obesity agents (orlistat, phentermine-topiramate, naltrexone-bupropion) typically achieve only modest weight loss (3-10%) and are limited by tolerability and safety concerns.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →